Eris Lifesciences Limited (ERIS.NS)
Manufactures prescription medicines for chronic diseases sold across India and globally
1,426.50+0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-21.1%
The outlook
Eris Lifesciences is trading near the lower end of its 52-week range, with analyst targets averaging around 19% above the current price. The stock shows mixed momentum against its moving averages, and the trailing P/E of 31.6 reflects a premium valuation relative to current earnings.
What’s behind the score
Price trendMixed vs its moving averages
52-week range33% of the way from its 52-week low to high
Price targetAvg target +19% vs current price
Analyst price target
~12-month · 10 analysts1,700.10average target+19.2% vs now
Now 1,426.50
Low 1,470.00High 1,940.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$197.68B
52-wk high
1,885.00
52-wk low
1,200.00
50-day avg
1,413.61
200-day avg
1,445.19
Trailing P/E
31.6